Combination Latency Reversal With High Dose Disulfiram Plus Vorinostat in HIV-infected Individuals on ART (DIVA): A Single Arm Clinical Trial
Phase of Trial: Phase I/II
Latest Information Update: 12 Apr 2019
Price : $35 *
At a glance
- Drugs Disulfiram (Primary) ; Vorinostat (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms DIVA
- 09 Apr 2019 Status changed from suspended to discontinued.
- 07 Mar 2019 Results presented at the 26th Conference on Retroviruses and Opportunistic Infections
- 19 Nov 2018 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2019.